Angioline, a Russian developer and manufacturer of medical products for invasive cardiology, was founded in 2007. The company's production facilities are located in Novosibirsk in the Technopark of Academgorodok.

Since 2009, the company has launched the Sinus coronary holometallic stents and the Kolibri balloon catheters. In 2011, the product portfolio of Angioline was enriched with more than 15 types of accessories for X-ray endovascular diagnosis and treatment of heart and vascular diseases. Also in 2011, the company developed the first domestic Calypso coronary stent with a drug coating.

All products manufactured by Angioline have registration certificates and declarations of conformity issued by Roszdravnadzor of the Russian Federation.

The main goal of Angioline is to provide domestic invasive cardiovascular X-ray surgery with coronary stents and consumables at prices acceptable for mass surgery. The cost of manufactured products favorably differs from the cost of foreign counterparts, not yielding to them in quality.

In addition, Angiolline conducts research to develop tools that can be used to prevent stroke, thromboembolism, as well as for the surgical treatment of glaucoma.

The company's priority is a high level of safety of the products. The production module is equipped with modern equipment from the USA; production technologies are introduced that ensure the safety and efficiency of products at the level of leading Western manufacturers. Since 2011, Angioline has insured the liability for the entire range of products for $ 5 million per year (with a limit of up to $ 2 million per 1 insured event).

Angioline products are presented in the Daksmed Group of Companies portfolio in the following areas: Angiography. Access and Diagnosis, Coronary Angioplasty